FDA to review NexMed NDA for erectile dysfunction drug
Fixes to reflect application’s acceptance for review, not drug’s approval NEW YORK, Nov. 20, 2007 (Thomson Financial delivered by Newstex) — NexMed Inc. (NASDAQ:NEXM) Tuesday said the new drug application for its proposed erectile dysfunction treatment has been accepted for review by the Food and Drug Administration.
NexMed is working with its partner Warner Chilcott to gain regulatory approval for the treatment.
Shares of Nexmed, an East Windsor, N.J.-based pharmaceutical company, rose 4.9% to $1.51 on Tuesday.
Ryan Vlastelica , Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
Related posts:
- Sanofi-Aventis To Help Market Lilly’s Cialis Impotence Drug
- Pfizer’s Dividend Needs Viagra
- United licenses drug indication to Lilly
- Local importer to stop bringing in imitation Viagra
- Eli Lilly (Cialis manufacturer) seen posting positive 1Q results
Comments
Leave a Reply
-
-
Recently Written
- Viagra and other fun with the health-care bill
- Cialis shown to help with muscle dystrophy
- Viagra aids in conceiving
- Virginia is for Viagra
- SIX MILLION MEN BUY VIAGRA ONLINE
- Viagra as a primary method of treatment of erectile dysfunction
- Generic Viagra will enable to get erection with Longer Effectiveness
- The Popularity Of Viagra Brings About A Cultural Change In Men
- Cialis Being Used To Treat Tumours
- Fake Viagra factory raided in Israel
-
Categories
